Efficacy and Tolerability of Stavudine plus Lamivudine in Treatment-Naive and Treatment-Experienced Patients with HIV-1 Infection

  1. Christine Katlama, MD;
  2. Marc-Antoine Valantin, MD;
  3. Sophie Matheron, MD;
  4. Anne Coutellier, MD;
  5. Vincent Calvez, MD;
  6. Diane Descamps, MD;
  7. Christophe Longuet, MD;
  8. Manuela Bonmarchand, MD;
  9. Roland Tubiana, MD;
  10. Marcio De Sa, MD;
  11. Remi Lancar, MSc;
  12. Henri Agut, MD;
  13. Francoise Brun-Vezinet, MD; and
  14. Dominique Costagliola, PhD
  1. From Hopital Pitie-Salpetriere, Hopital Bichat-Claude Bernard, and INSERM SC4, Institut Saint Antoine de Recherche en Sante, Paris, France. Grant Support: By Agence Nationale de Recherche sur le SIDA, Paris, France. Acknowledgments: The authors thank the study and manuscript staff members who contributed to the study; the participants; the technical assistant (M. Pauchard); the pharmacists (M.H. Fievet, PhD, and A. Certain, PhD); Bristol-Myers Squibb, Inc. (J.J Gres, MD, and P. Ngovan, MD), and Glaxo Wellcome (D. Lapierre, MD, and A. Fetter, MD), which contributed study medication; and J. Hawes for assistance in manuscript preparation. Requests for Reprints: Christine Katlama, MD, Department of Infectious Diseases, Hopital Pitie-Salpetriere, 47, Boulevard de l'Hopital, 75013 Paris, France. Current Author Addresses: Drs. Katlama, Valantin, Tubiana, De Sa, and Agut: Department of Infectious Diseases, Hopital Pitie-Salpetriere, 47, Boulevard de l'Hopital, 75013 Paris, France.
     
    Next Section

    Abstract

    Background: A combination of two nucleoside analogues is currently the core of any antiretroviral regimen for HIV-1 infection. Stavudine plus lamivudine has shown an additive effect in vitro, as well as an absence of overlapping toxicity and cross-resistance.

    Objective: To evaluate the antiviral efficacy of stavudine plus lamivudine in treatment-naive patients and in patients previously treated with other nucleoside reverse transcriptase inhibitors.

    Design: Prospective, open-label pilot study.

    Setting: Three urban clinical centers in Paris.

    Patients: 83 patients with CD4+ cell counts between 50 and 400 cells/mm3 (42 treatment-naive and 41 treatment-experienced patients).

    Interventions: Stavudine, 40 mg twice daily (30 mg twice daily in patients with a body weight ≤ 60 kg), and lamivudine, 150 mg twice daily.

    Measurements: Primary end points for efficacy included changes in plasma viral load and CD4+ cell count at 24 weeks compared with baseline.

    Results: Therapy with stavudine plus lamivudine resulted in a median decrease of 1.66 log10 (101.66) (range, −3.04 to −0.79 log10) in plasma HIV-1 RNA; the median increase in CD4+ cell count was 108 cells/mm3 (range, −58 to 406 cells/mm3) at week 24 in treatment-naive patients. In treatment-experienced patients, the median reduction in plasma HIV-1 RNA was 0.55 log10 (range, −2.86 to 0.52 log10), and the median increase in CD4+ cell count was 46 cells/mm3 (range, −188 to 311 cells/mm3). The percentages of patients with less than 3000 HIV-1 RNA copies/mL and less than 400 copies/mL at 24 weeks were, respectively, 57% (95% CI, 41% to 72%) and 26% (CI, 12% to 40%) among treatment-naive patients and 22% (CI, 10% to 38%) and 5% (CI, 1% to 17%) among treatment-experienced patients. Of 82 patients, 14 (17%) experienced grade 3 or 4 toxicity and 2 discontinued therapy because of intolerance toward treatment.

    Conclusion: Stavudine plus lamivudine seems to have a potent antiviral effect in treatment-naive and treatment-experienced patients. No major drug-limiting toxicity was found. This two-nucleoside combination should be considered in multidrug therapy for HIV.

    In the past few years, the recommended treatment for HIV-1 infection has changed from monotherapy with zidovudine to combination therapies with two or more drugs because of the higher potency of these drugs against viral replication. Combination therapies have delayed disease progression in both asymptomatic and profoundly immunosuppressed patients [1-3]. Historically, most nucleoside analogue combinations evaluated in clinical trials have contained zidovudine. However, because of patient intolerance, development of resistance to zidovudine [4], or progressive failure of zidovudine therapy, it is important to evaluate combinations of nucleoside analogues that do not include zidovudine.

    Stavudine has shown potent antiviral activity when used as monotherapy in patients with asymptomatic or advanced HIV-1 infection [5-8], as well as clinical efficacy in zidovudine-experienced patients [9]. Stavudine plus didanosine has shown potent antiviral and immunologic efficacy [10]. Lamivudine has been studied primarily in combination therapy with zidovudine in both treatment-naive and treatment-experienced patients and has been shown to have clinical benefit due to its potent antiviral activity [3, 11-14]. Although treatment with lamivudine results in the rapid selection of the mutation on the reverse transcriptase gene at codon 184 and the development of phenotypic resistance [15, 16], only a partial loss of viral activity occurs [11-1417, 18]. Furthermore, this mutation has been shown to cause zidovudine-resistant virus to reacquire susceptibility to zidovudine [19]. Stavudine and lamivudine have additive or synergistic activity against both zidovudine-sensitive and zidovudine-resistant HIV-1 strains in vitro [20]. In vitro studies have also shown that prolonged treatment with stavudine is generally not associated with the development of high levels of viral resistance to the drug [21].

    Our open-label pilot study, which is known as ALTIS, was designed to evaluate therapy with stavudine plus lamivudine in patients who had never before received an antiretroviral agent and those who had previously received antiretroviral agents other than stavudine or lamivudine.

    Previous SectionNext Section

    Methods

    Study Design and Patients

    We conducted a 24-week open-label pilot study at three clinical centers in Paris to evaluate the virologic and immunologic efficacy and safety of stavudine plus lamivudine. Major inclusion criteria were age 18 years or older, seropositivity for HIV-1 confirmed by Western blot, CD4+ cell count between 50 and 400 cells/mm3, HIV-1 RNA plasma viral load of more than 15 000 copies/mL, Karnofsky performance score of at least 70, and no previous use of stavudine or lamivudine. Patients were also required to have a hemoglobin level of 80 g/L or more, a total neutrophil count of more than 750 cells/mm3, a platelet count of more than 50 000 cells/mm3, a liver enzyme level no more than 5 times the upper limit of normal, a serum creatinine concentration no more than 1.5 times the upper limit of normal, and a lipase level less than 2 times the upper limit of normal. Patients at any stage of HIV disease were recruited and were divided into two subgroups: those who had not previously received any antiretroviral drugs and those who had received zidovudine, didanosine, zalcitabine, or any combination of two of these drugs.

    The study protocol was approved by the institutional review board of the Groupe Hospitalier Pitie-Salpetriere. Each patient provided written informed consent.

    Treatment Regimen

    Patients were given stavudine, 30 mg twice daily if their body weight was 60 kg or less or 40 mg twice daily if their body weight was more than 60 kg, and lamivudine, 150 mg twice daily. This combination was administered for 24 weeks. Concomitant therapies, except for other antiretroviral or immune-based therapies, were allowed if they were required by the patient's condition. Prophylaxis against Pneumocystis carinii and Toxoplasma gondii was recommended for all patients with a CD4+ count less than 200 cells/mm3; the decision to institute such prophylaxis and the type of prophylaxis were left to the physician and patient.

    Clinical and Laboratory Evaluations

    Patients were evaluated within the 2 weeks before the start of the study; at day 0, week 2, and week 4; and then every 4 weeks through week 24. Screening and baseline evaluations included a full medical history. At each visit, patients were questioned about any new clinical or physical events that may have indicated clinical progression or adverse events; adverse events were judged according to the AIDS Clinical Trials Group system. At each visit, vital signs, clinical signs or symptoms, and Karnofsky score were recorded, and complete blood cell counts, biochemical tests, CD4+ and CD8+ lymphocyte counts, and quantitative plasma viral load were measured. The HIV-1 RNA viral load was measured by using a quantitative polymerase chain reaction assay with a lower limit of detection of 200 copies/mL (Roche Amplicor monitor system, Roche, Branchburg, New Jersey). The HIV-1 RNA viral load was measured on acid citrate dextrose plasma samples that were immediately frozen and stored at −80°C.Specimens for each patient were batch tested with a negative control and two positive controls (low, 10 000 to 20 000 copies/mL; high, 300 000 to 400 000 copies/mL). All analyses were performed with the same lot of reagents.

    Criteria for Efficacy

    Measures of virologic efficacy were evaluated by using the difference between the baseline HIV-1 RNA value (geometric mean of the screening and the entry value) and the value at week 24. Initially, the protocol stated that the treatment would be considered effective if the median decrease in plasma viral load at week 24 was at least 0.6 log10. However, in accordance with standard current practice, we chose to consider a decrease in viral load of at least 1 log10 as clinically significant. Other measures included the percentage of patients with a viral load of 3000 HIV-1 RNA copies/mL or less or 400 copies/mL or less and the percentage of patients with an increase in CD4+ cell count of 50 cells/mm3 or more or 50% or more compared with baseline values.

    Statistical Analysis

    Data were analyzed from all patients who received at least one dose of the study treatment. For the six treatment-experienced patients who stopped taking the study treatment before week 24, the last-observation-carried-forward technique was used to analyze viral load and CD4+ count [22]. With this technique, the missing value at a given week is replaced by the last value observed during the trial treatment. This procedure was followed because most of these patients were switched to a more potent antiretroviral regimen, and intention-to-treat analysis tended to overestimate the treatment effect of stavudine plus lamivudine. Analyses of virologic and immunologic variables and of tolerance were mainly descriptive in nature. A graph representing the absolute difference between viral load at week 24 and at baseline was drawn to ascertain the percentage of patients in whom the maximal efficacy was observed (the difference between the baseline viral load and the threshold of the technique was used to measure the viral load).

    Role of Study Sponsor

    Stavudine (Zerit) was provided by Bristol-Myers Squibb Paris (France), and lamivudine (Epivir) was provided by Glaxo Wellcome Paris (France). Data were gathered, analyzed, and interpreted independently of the pharmaceutical companies that provided the drugs, according to the monitoring and operating procedures of the Agence Nationale de Recherche sur le SIDA.

    Previous SectionNext Section

    Results

    Demographic and Clinical Characteristics

    A total of 83 patients were recruited into the study (42 treatment-naive patients and 41 treatment-experienced patients). Baseline characteristics are listed in Table 1. Most of the patients were male (85.5%), and 83% had acquired HIV-1 infection through sexual contact. Treatment-naive patients were predominantly asymptomatic (71%) and had a median baseline CD4+ cell count of 258 cells/mm3 and a median viral load of 76 502 HIV-1 RNA copies/mL (4.88 log10). Treatment-experienced patients were more frequently symptomatic; 59% had stage B or C symptoms according to Centers for Disease Control and Prevention criteria. The median CD4+ cell count was 172 cells/mm3, and the median viral load was 91 255 HIV-1 RNA copies/mL (4.96 log10). Among the treatment-experienced patients, the median duration of previous treatment was 35 months (range, 4 to 94 months); 49% of patients had received monotherapy, and 51% had received nucleoside combination therapy.

    View this table:
    Table 1. Baseline Characteristics*

    Of the 83 patients enrolled in the trial, 77 completed 24 weeks of therapy (42 of 42 in the treatment-naive group and 35 of 41 in the treatment-experienced group). Discontinuation or modification to the allocation of study drugs was due to loss to follow-up at week 4 (1 patient), lymphoma at week 9 (1 patient), adverse events at week 15 (1 patient) and week 20 (1 patient), and biological progression of HIV disease at week 16 (2 patients).

    Changes in Viral Load and CD4+ Cell Count

    Viral load decreased and CD4+ cell counts increased after treatment with stavudine plus lamivudine in both treatment-naive and treatment-experienced patients. The virologic and immunologic response profile differed between the groups. In the treatment-naive patients, a median reduction in plasma HIV-1 RNA of 1.96 log (10) (range, −2.76 to −0.70)was observed after 4 weeks of stavudine plus lamivudine therapy, which was sustained at a median reduction of 1.66 log10 (range, −3.04 to −0.79)at week 24 (Figure 1). In the treatment-experienced patients, the median maximum reduction in plasma HIV-1 RNA was 1.32 log10 (range, −3.13 to 0.49) after 4 weeks, followed by a rebound in virus production, resulting in a final median plasma HIV-1 RNA reduction of 0.55 log10 (range, −2.86 to 0.52) below baseline at week 24. After 24 weeks of therapy, 86% of patients (95% CI, 75% to 97%) in the treatment-naive group and 34% of patients (CI, 19% to 49%) in the treatment-experienced group had a decrease in plasma HIV-1 RNA of 1 log10 or more. A viral load of less than 3000 HIV-1 RNA copies/mL was recorded in 57% of patients (CI, 41% to 72%) in the treatment-naive group and 22% of patients (CI, 10% to 38%) in the treatment-experienced group. A viral load of less than 400 HIV-1 RNA copies/mL was found in 26% of patients (CI, 12% to 40%) in the treatment-naive group and 5% of patients (CI, 1% to 17%) in the treatment-experienced group. In patients whose viral load reached 400 copies/mL at week 24, the mean baseline viral load was 32 700 copies/mL (CI, 16 160 to 66 150 copies/mL) compared with 99 980 copies/mL (CI, 62 360 to 160 320) in patients whose viral load remained above 400 copies/mL (P = 0.05). The treatment-naive patients who attained optimal viral treatment efficacy were those who had a lower viral load before initiation of combination therapy (Figure 2).

    Figure 1. The numbers in parentheses are the numbers of treatment-naive patients/treatment-experienced patients.
    View larger version:
    Figure 1. The numbers in parentheses are the numbers of treatment-naive patients/treatment-experienced patients. Median decrease in plasma viral load for treatment-naive (circles) and treatment-experienced (squares) patients over 24 weeks of therapy with stavudine plus lamivudine.
    Figure 2. The solid diagonal line represents the maximum benefit in viral load reduction that can be measured by using a technique with a lower limit of detection of 400 copies/mL. Thus, no data point (▵) can be located beyond this line. The closer the data point is to the line, the greater the efficacy of treatment.
    View larger version:
    Figure 2. The solid diagonal line represents the maximum benefit in viral load reduction that can be measured by using a technique with a lower limit of detection of 400 copies/mL. Thus, no data point (▵) can be located beyond this line. The closer the data point is to the line, the greater the efficacy of treatment. Individual decrease in HIV-1 RNA viral load after 24 weeks measured against baseline HIV-1 RNA in treatment-naive patients.

    The immunologic response to stavudine plus lamivudine mirrored the virologic response (Figure 3). Among the treatment-naive patients, a rapid CD4+ cell count increase that reached a median of 90 cells/mm3 (range, −85 to 302 cells/mm3) was seen at week 4, followed by a progressive, slower increase that reached a median of 108 cells/mm3 (range, −58 to 406 cells/mm3) at week 24. In treatment-experienced patients, a median increase in CD4+ cell count of 45 cells/mm3 (range, −64 to 166 cells/mm3) was found at week 4, which was sustained at 46 cells/mm3 (range, −188 to 311 cells/mm3) above baseline at week 24.

    Figure 3. The numbers in parentheses are the numbers of treatment-naive patients/treatment-experienced patients.
    View larger version:
    Figure 3. The numbers in parentheses are the numbers of treatment-naive patients/treatment-experienced patients. Median changes in CD4+ cell counts for treatment-naive (circles) and treatment-experienced (squares) patients over 24 weeks of therapy with stavudine plus lamivudine.

    After 24 weeks of therapy, 71% (CI, 54% to 85%) of treatment-naive patients and 34% (CI, 19% to 51%) of treatment-experienced patients had a minimum increase of 50 CD4 cells/mm3. A minimum increase in CD4 cells of 50% was observed at week 24 in 50% (CI, 34% to 66%) of treatment-naive and 37% (CI, 22% to 53%) of treatment-experienced patients.

    Safety

    Adverse events are reported in Table 2. Overall, 17% (CI, 9% to 27%) of the 82 patients with more than 4 weeks of follow-up experienced grade 3 or 4 toxicity. The most common grade 3 or 4 laboratory adverse events were elevated aspartate aminotransferase and alanine aminotransferase levels (7% [CI, 3% to 15%]), increased creatine phosphokinase levels (5% [CI, 1% to 12%]), increased lactate dehydrogenase levels (1% [CI, 0% to 6%]), and increased levels of amylase and lipase (1% [CI, 0% to 6%]). Eight patients experienced grade 1 or 2 paresthesia during the study. Two patients discontinued therapy because of intolerance.

    View this table:
    Table 2. Clinical and Laboratory Adverse Events
    Previous SectionNext Section

    Discussion

    Nucleoside analogues are the core of all antiretroviral therapeutic regimens. Because antiretroviral combinations that do not include zidovudine are increasingly used in clinical practice, it is important to identify and characterize potent two-nucleoside combinations with favorable antiviral efficacy and safety profiles as alternatives to regimens containing zidovudine.

    Our 24-week, open-label study showed that stavudine plus lamivudine is a potent antiviral two-nucleoside combination, resulting in a median viral reduction of 1.66 log10 in treatment-naive patients and a reduction of 0.55 log10 in patients previously exposed to a nucleoside analogue other than stavudine or lamivudine. We did not compare stavudine plus lamivudine with other therapies or placebo.

    In treatment-naive patients, the greatest reduction in plasma HIV-1 RNA occurred at week 4 (1.96 log10). A reduction in plasma HIV-1 RNA of 1.66 log (10) was sustained over the 24-week study period. Of interest, although direct comparison among trials is only indicative, the kinetics of this virologic response over 24 weeks in treatment-naive patients differs slightly from that observed in two trials evaluating zidovudine plus lamivudine in treatment-naive patients [11, 12]. In those studies, a similar maximum peak reduction in viral load of approximately 1.5 log10 was followed by a rebound in viral production leading to a median reduction of 1 log10 over 24 weeks.

    One of the main interpretations of the rebound in viral load after 4 to 8 weeks of therapy with zidovudine plus lamivudine has been the rapid selection of viral populations containing the methionine-to-valine mutation at amino acid 184 of reverse-transcriptase enzyme. However, the preliminary data in our study on reverse-transcriptase sequencing show that five of six treatment-naive patients had the M184V mutation at week 12; the sixth patient had a mixed wild and mutant viral population (data not shown). Therefore, the absence of viral rebound is unlikely to be explained by an absence of M184V mutation with lamivudine therapy. In treatment-naive patients, there seem to be two slopes of the increasing CD4+ cell count curve-an initial rapid increase of 90 cells/mm3 above baseline during the first 4 weeks, followed by a slightly progressive increase up to 108 cells/mm3 above baseline at week 24. This pattern may be due to the increase of two different lymphocyte populations: the acutely infected CD4+ cells that are no longer being killed by the viral production, leading to a rapid increase in CD4+ cells, followed by a less pronounced increase of CD4+ cells that may correspond to a subset of the chronically infected cell population, which has a less rapid turnover [23].

    In patients who had previously received other nucleoside analogues, the virologic and immunologic responses to therapy followed a different pattern. The greatest reduction in plasma HIV-1 RNA was achieved at week 4 (1.32 log10 copies/mL) and was followed by a rebound, bringing the final reduction in viral load at week 24 to 0.55 log10. This pattern of virologic rebound after 4 weeks of therapy is similar to data reported in patients pretreated with zidovudine plus lamivudine [13, 14], zidovudine plus didanosine, or zidovudine plus zalcitabine [23]. The increase in CD4+ cell count at week 4 (45 cells/mm3) was sustained at week 24.

    The difference in the efficacy profile of stavudine plus lamivudine in treatment-naive patients compared with treatment-experienced patients (a difference of approximately 1 log10 in the viral load reduction and 60 CD4+ cells/mm3 in the CD4+ cell count increase in favor of treatment-naive patients) is intriguing. Because neither population had previously received stavudine or lamivudine, one can speculate that preexposure to nucleoside analogues that have been unsuccessful in profoundly reducing the viral load reduces the potency of a new combination of nucleoside analogues. Preliminary data on complete sequencing of the virus suggest that primary resistance of HIV-1 to stavudine in the pretreated patients can be ruled out because the sequencing of the virus at baseline did not show genotypic resistance to any of the viral mutations associated with stavudine resistance (those on codon 75 or codon 50). Furthermore, these data suggest that the rapid appearance of lamivudine resistance due to the high frequency (>90%) of acquisition of the M184V mutation within a few weeks after initiating any lamivudine-containing regimen occurs similarly in both treatment groups (data not shown). Another explanation may be that previous exposure to other nucleoside analogues modifies the intracellular pharmacodynamics of lamivudine's metabolism, leading to changes in intracellular phosphorylation that may decrease the blood concentration of the active metabolite of nucleoside analogue [24]. Stavudine has an interesting resistance profile: To date, it has been difficult to clearly identify any mutations associated with phenotypic resistance [21]. This suggests that stavudine may play an important role as a part of first-line multiple antiretroviral therapy.

    Until now, few direct comparisons of nucleoside analogue combinations have been made, despite their extensive use in clinical practice. The most extensively studied combinations have been zidovudine plus didanosine, zidovudine plus zalcitabine (which has shown an approximate reduction in HIV-1 RNA of 0.8 to 1 log10), and zidovudine plus lamivudine [11, 12, 23-26]. In the absence of a true comparative trial, it is impossible to stratify therapies according to their antiviral power. However, the performance of stavudine plus lamivudine in this trial, with a viral load reduction of about 1.5 log10 in treatment-naive patients and 0.5 log10 in pretreated patients, compares favorably with that of the standard, widely studied zidovudine plus lamivudine combination or didanosine plus stavudine regimens.

    The combination of stavudine and lamivudine was well tolerated by both treatment-naive and treatment-experienced patients. Only two patients discontinued therapy as a result of intolerance, and no patients experienced greater than grade 2 neurologic symptoms. Seventeen percent of patients experienced at least one grade 3 or grade 4 event, most often elevations of aminotransferase levels. The high tolerability of this combination may result from largely nonoverlapping toxicity profiles and the good safety profile of each drug.

    In summary, the strong antiretroviral activity of stavudine plus lamivudine, the simplicity of the dosing schedule, and the good safety profile make this two-nucleoside combination potentially attractive as an option in multidrug therapy for HIV.

    Drs. Coutellier and Bonmarchand: Department of Medicine, Hopital Pitie-Salpetriere, 47, Boulevard de l'Hopital, 75013 Paris, France.

    Drs. Matheron and Longuet: Department of Infectious Diseases, Hopital Bichat-Claude Bernard, 46, rue H. Huchard, 75018 Paris, France.

    Drs. Calvez and Agut: Department of Virology, Hopital Pitie-Salpetriere, 47, Boulevard de l'Hopital, 75013 Paris, France.

    Drs. Descamps and Brun-Vezinet: Department of Virology, Hopital Bichat-Claude Bernard, 46, rue H. Huchard, 75018 Paris, France.

    Mr. Lancar and Dr. Costagliola: INSERM SC4, 27, rue de Chaligny, 75012 Paris, France.

    Previous Section
     

    References

    1. 1.↵
      Hammer SM, Katzenstein DA, Hughes MD, Gundacker MS, Schooley RT, Haubrich RH, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med. 1996; 335:1081-90.
    2. 2.↵
      Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Delta Coordinating Committee. Lancet. 1996; 348:283-91.
    3. 3.↵
      Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 1997; 349:1413-21.
    4. 4.↵
      D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, et al. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 1168/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med. 1995; 122:401-8.
    5. 5.↵
      Griffith BP, Brett-Smith H, Kim G, Mellors JW, Chacko TM, Garner RB, et al. Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia. J Infect Dis. 1996; 173:1252-5.
    6. 6.↵
      Murray HW, Squires KE, Weiss W, Sledz S, Sacks HS, Hassett J, et al. Stavudine in patients with AIDS and AIDS-related complex: AIDS Clinical Trials Group 089. J Infect Dis. 1995; 171 Suppl 2:S123-30.
    7. 7.↵
      Petersen EA, Ramirez-Ronda CH, Hardy WD, Schwartz R, Sacks HS, Follansbee S, et al. Dose-related activity of stavudine in patients infected with human immunodeficiency virus. J Infect Dis. 1995; 171 Suppl 2:S131-9.
    8. 8.↵
      Katlama C, Molina JM, Rozenbaum W, Valantin MA, Modai J, Chauveau E, et al. Stavudine (d4T) in HIV infected patients with CD4 less than 350/mm3: results of a double-blind randomized placebo controlled study [Abstract]. Program and Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 28 January-1 February 1996:196.
    9. 9.↵
      Spruance SL, Pavia AT, Mellors JW, Murphy R, Gathe J Jr, Stool E, et al. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients. A randomized, double-blind, controlled trial. Bristol-Myers Squibb Stavudine/019 Study Group. Ann Intern Med. 1997; 126:355-63.
    10. 10.↵
      Pollard R, Peterson D, Hardy D, Pedneault L, McLaren C, Skovronski J, et al. Antiviral effect and safety of stavudine (d4T) and didanosine (ddl) combination therapy in HIV-infected subjects in an ongoing pilot randomized double-blinded trial [Abstract]. Program and Abstracts of the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 28 January-1 February 1996.
    11. 11.↵
      Eron JJ, Benoit SL, Jemsek J, MacArthur RD, Santana J, Quinn JB, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med. 1995; 333:1662-9.
    12. 12.↵
      Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA. 1996; 276:118-25.
    13. 13.↵
      Staszewski S, Loveday C, Picazo JJ, Dellamonica P, Skinhoj P, Johnson MA, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group. JAMA. 1996; 276:111-7.
    14. 14.↵
      Bartlett JA, Benoit SL, Johnson VA, Quinn JB, Sepulveda GE, Ehmann WC, et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. Ann Intern Med. 1996; 125:161-72.
    15. 15.↵
      Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995; 171:1411-9.
    16. 16.↵
      Wainberg MA, Drosopoulos WC, Salomon H, Hsu M, Borkow G, Parniak MA, et al. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science. 1996; 271:1282-5.
    17. 17.↵
      van Leeuwen R, Katlama C, Kitchen V, Boucher CA, Tubiana R, McBride M, et al. Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis. 1995; 171:1166-71.
    18. 18.↵
      Pluda JM, Cooley TP, Montaner JS, Shay LE, Reinhalter NE, Warthan SN, et al. A phase I/II study of 2′-deoxy-3′-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection. J Infect Dis. 1995; 171:1438-47.
    19. 19.↵
      Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995; 269:696-9.
    20. 20.↵
      Merrill DP, Moonis M, Chou TC, Hirsch MS. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. J Infect Dis. 1996; 173:355-64.
    21. 21.↵
      Lin PF, Samanta H, Rose RE, Patick AK, Trimble J, Bechtold CM, et al. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J Infect Dis. 1994; 170:1157-64.
    22. 22.↵
      Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trial. Drug Information Journal. 1991; 25:411-24.
    23. 23.↵
      Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature. 1997; 387:188-91.
    24. 24.↵
      Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med. 1996; 335:1091-8.
    25. 25.↵
      Sommadossi JP, Valantin MA, Zhou XJ, Xie MY, Moore J, Calvez V, et al. Intracellular phosphorylation of stavudine (d4T) and 3TC correlates with their antiviral activity in naive and zidovudine (ZDV) experienced HIV-infected patients [Abstract]. Program and Abstracts of the 5th Conference on Retroviruses and Opportunistic Infections, Chicago, 1-5 February 1998:362.
    26. 26.↵
      Saravolatz LD, Winslow DL, Collins G, Hodges JS, Pettinelli C, Stein DS, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. Investigators for the Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. 1996; 335:1099-106.
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med October 1, 1998 vol. 129 no. 7 525-531
    1. AbstractFREE
    2. Figures
    3. » Full Text
    4. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Navigate This Article

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues